Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1989 1
1990 1
1993 2
1994 14
1995 22
1996 22
1997 20
1998 20
1999 25
2000 28
2001 28
2002 43
2003 37
2004 37
2005 36
2006 28
2007 35
2008 48
2009 50
2010 41
2011 38
2012 43
2013 36
2014 29
2015 29
2016 23
2017 19
2018 15
2019 19
2020 20
2021 10
2022 26
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

801 results

Results by year

Filters applied: . Clear all
Page 1
HIV vaccines.
McMichael AJ. McMichael AJ. Annu Rev Immunol. 2006;24:227-55. doi: 10.1146/annurev.immunol.24.021605.090605. Annu Rev Immunol. 2006. PMID: 16551249 Review.
HIV vaccines: sin boldly!
Cohen GB. Cohen GB. AIDS. 2010 Nov 27;24(18):2877-9. doi: 10.1097/QAD.0b013e328340fefc. AIDS. 2010. PMID: 21063176 No abstract available.
The role of adjuvants in retroviral vaccines.
Vogel FR. Vogel FR. Int J Immunopharmacol. 1995 Feb;17(2):85-90. doi: 10.1016/0192-0561(94)00095-6. Int J Immunopharmacol. 1995. PMID: 7657411 Review.
Vaccines composed of subunit antigens generally are considered to be safer than traditional whole-killed or live-attenuated vaccines. However, purified subunit vaccines often are inherently less immunogenic than traditional vaccines. ...
Vaccines composed of subunit antigens generally are considered to be safer than traditional whole-killed or live-attenuated vaccin …
Oral Vaccination Approaches for Anti-SHIV Immunity.
Velarde de la Cruz E, Wang L, Bose D, Gangadhara S, Wilson RL, Amara RR, Kozlowski PA, Aldovini A. Velarde de la Cruz E, et al. Front Immunol. 2021 Jun 21;12:702705. doi: 10.3389/fimmu.2021.702705. eCollection 2021. Front Immunol. 2021. PMID: 34234789 Free PMC article.
Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques.
Rahman MA, Bissa M, Silva de Castro I, Helmold Hait S, Stamos JD, Bhuyan F, Hunegnaw R, Sarkis S, Gutowska A, Doster MN, Moles R, Hoang T, Miller Jenkins LM, Appella E, Venzon DJ, Choo-Wosoba H, Cardozo T, Baum MM, Appella DH, Robert-Guroff M, Franchini G. Rahman MA, et al. Nat Microbiol. 2023 May;8(5):905-918. doi: 10.1038/s41564-023-01353-7. Epub 2023 Apr 6. Nat Microbiol. 2023. PMID: 37024617 Free PMC article.
Human immunodeficiency virus-1 vaccine design: where do we go now?
Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C. Wijesundara DK, et al. Immunol Cell Biol. 2011 Mar;89(3):367-74. doi: 10.1038/icb.2010.118. Epub 2010 Oct 19. Immunol Cell Biol. 2011. PMID: 20956986 Review.
The failures and limited successes of HIV-1 vaccines have highlighted the gaps in our knowledge with regard to fundamental immunity against HIV-1 and have provided insights for vaccine strategies that may be implemented for designing more effective HIV-1 vaccines in …
The failures and limited successes of HIV-1 vaccines have highlighted the gaps in our knowledge with regard to fundamental immunity a …
Vaccine protection against SIVmac239 acquisition.
Martins MA, Bischof GF, Shin YC, Lauer WA, Gonzalez-Nieto L, Watkins DI, Rakasz EG, Lifson JD, Desrosiers RC. Martins MA, et al. Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1739-1744. doi: 10.1073/pnas.1814584116. Epub 2019 Jan 14. Proc Natl Acad Sci U S A. 2019. PMID: 30642966 Free PMC article.
Development of an AIDS vaccine using Sendai virus vectors.
Ishii H, Matano T. Ishii H, et al. Vaccine. 2015 Nov 9;33(45):6061-5. doi: 10.1016/j.vaccine.2015.06.114. Epub 2015 Jul 29. Vaccine. 2015. PMID: 26232346 Review.
Its immunogenicity and protective efficacy have been shown, indicating that the SeV vector is a promising delivery tool for AIDS vaccines. Here, we describe the potential of SeV vector as a vaccine antigen delivery tool to induce effective immune responses against HIV-1 in …
Its immunogenicity and protective efficacy have been shown, indicating that the SeV vector is a promising delivery tool for AIDS vaccines …
Attenuated vaccines for AIDS.
Victorino RM, Sousa AE. Victorino RM, et al. Lancet. 1995 Jul 15;346(8968):179. Lancet. 1995. PMID: 7603240 No abstract available.
801 results